Nidanilimab Biosimilar - Anti-IL1RAP mAb - Research Grade
Source
CAS 2171061-85-9
Species
Humanized
Expression system
Mammalian cells
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Nidanilimab ,CAN-04,,IL1RAP,anti-IL1RAP
Reference
PX-TA1571
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1-kappa
Clonality
Monoclonal Antibody
Description of Nidanilimab Biosimilar - Anti-IL1RAP mAb - Research Grade
Introduction
Nidanilimab, also known as Anti-IL1RAP mAb, is a biosimilar antibody that has been developed as a potential therapeutic for various inflammatory diseases. This article will provide a scientific description of the structure, activity, and application of Nidanilimab, with a focus on its potential as a therapeutic targeting IL1RAP.
Structure of Nidanilimab
Nidanilimab is a monoclonal antibody, meaning it is derived from a single type of immune cell. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chains consist of constant and variable regions, while the light chains consist of only variable regions. The variable regions are responsible for binding to the target molecule, in this case, IL1RAP.
Activity of Nidanilimab
Nidanilimab specifically targets and binds to IL1RAP, which is a cell surface receptor for the pro-inflammatory cytokine interleukin-1 (IL-1). By binding to IL1RAP, Nidanilimab blocks the binding of IL-1 and prevents its signaling. This results in a decrease in the production of pro-inflammatory cytokines and a reduction in inflammation.
Application of Nidanilimab
Nidanilimab has shown potential as a therapeutic for various inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. IL1RAP is known to play a crucial role in the development and progression of these diseases, making it a promising therapeutic target.
In preclinical studies, Nidanilimab has been shown to effectively reduce inflammation and improve symptoms in animal models of rheumatoid arthritis and psoriasis. In a phase 1 clinical trial, Nidanilimab was found to be safe and well-tolerated in healthy volunteers, with no serious adverse events reported.
Currently, Nidanilimab is in phase 2 clinical trials for the treatment of rheumatoid arthritis and psoriasis. These studies aim to evaluate the safety and efficacy of Nidanilimab in patients with these diseases. If successful, Nidanilimab could provide a much-needed treatment option for patients with inflammatory diseases.
Conclusion
Nidanilimab, a biosimilar anti-IL1RAP mAb, is a promising therapeutic targeting IL1RAP. Its specific binding to IL1RAP and inhibition of IL-1 signaling make it a potential treatment for various inflammatory diseases. With ongoing clinical trials, Nidanilimab could soon be a valuable addition to the arsenal of therapies available for patients with inflammatory diseases.
Reviews
There are no reviews yet.